Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Argus Health
Julphar
Teva
Accenture
Boehringer Ingelheim
Cerilliant
McKinsey
AstraZeneca

Generated: June 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 078012

« Back to Dashboard

NDA 078012 describes GEMFIBROZIL, which is a drug marketed by Mylan, Purepac Pharm, Apotex, Aurobindo Pharma Ltd, Cadila Pharms Ltd, Caribe Holdings, Chartwell Molecules, Hikma Pharms, Impax Pharms, Invagen Pharms, Northstar Hlthcare, Sun Pharm Inds Inc, Teva, Watson Labs, and Yaopharma Co Ltd, and is included in eighteen NDAs. It is available from fifty suppliers. Additional details are available on the GEMFIBROZIL profile page.

The generic ingredient in GEMFIBROZIL is gemfibrozil. Fifty-one suppliers are listed for this compound. Additional details are available on the gemfibrozil profile page.
Summary for 078012
Tradename:GEMFIBROZIL
Applicant:Caribe Holdings
Ingredient:gemfibrozil
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 078012
Medical Subject Heading (MeSH) Categories for 078012
Suppliers and Packaging for NDA: 078012
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
GEMFIBROZIL gemfibrozil TABLET;ORAL 078012 ANDA PuraCap Laboratories LLC dba Blu Pharmaceuticals 24658-260 N 24658-260-05
GEMFIBROZIL gemfibrozil TABLET;ORAL 078012 ANDA PuraCap Laboratories LLC dba Blu Pharmaceuticals 24658-260 N 24658-260-18

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength600MG
Approval Date:Mar 26, 2007TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Daiichi Sankyo
Fish and Richardson
Johnson and Johnson
Medtronic
Farmers Insurance
Colorcon
Argus Health
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.